Anti-Ad26 humoral immunity does not compromise SARS-COV-2 neutralizing antibody responses following Gam-COVID-Vac booster vaccination

[1]  V. Sintchenko,et al.  Improved Neutralisation of the SARS-CoV-2 Omicron Variant following a Booster Dose of Pfizer-BioNTech (BNT162b2) COVID-19 Vaccine , 2022, Viruses.

[2]  V. Simon,et al.  mRNA-1273 but not BNT162b2 induces antibodies against polyethylene glycol (PEG) contained in mRNA-based vaccine formulations , 2022, Vaccine.

[3]  S. Coppens,et al.  Three doses of BNT162b2 vaccine confer neutralising antibody capacity against the SARS-CoV-2 Omicron variant , 2022, NPJ vaccines.

[4]  A. Gorchakov,et al.  Memory B Cells Induced by Sputnik V Vaccination Produce SARS-CoV-2 Neutralizing Antibodies Upon Ex Vivo Restimulation , 2022, Frontiers in Immunology.

[5]  J. Mascola,et al.  SARS-CoV-2 Omicron Variant Neutralization after mRNA-1273 Booster Vaccination , 2022, The New England journal of medicine.

[6]  M. Koopmans,et al.  Immunogenicity and Reactogenicity of Vaccine Boosters after Ad26.COV2.S Priming , 2022, The New England journal of medicine.

[7]  Christina C. Chang,et al.  mRNA-based COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 Omicron variant , 2022, Cell.

[8]  V. Gushchin,et al.  An open, non-randomised, phase 1/2 trial on the safety, tolerability, and immunogenicity of single-dose vaccine “Sputnik Light” for prevention of coronavirus infection in healthy adults , 2021, The Lancet Regional Health - Europe.

[9]  A. Gorchakov,et al.  Isolation of a panel of ultra-potent human antibodies neutralizing SARS-CoV-2 and viral variants of concern , 2021, Cell discovery.

[10]  K. Stiasny,et al.  Distinguishing features of current COVID-19 vaccines: knowns and unknowns of antigen presentation and modes of action , 2021, NPJ vaccines.

[11]  Aaron M. Rosenfeld,et al.  Distinct antibody and memory B cell responses in SARS-CoV-2 naïve and recovered individuals following mRNA vaccination , 2021, Science Immunology.

[12]  V. Gushchin,et al.  Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia , 2021, The Lancet.

[13]  G. Efimov,et al.  Pattern of circulating SARS‐CoV‐2‐specific antibody‐secreting and memory B‐cell generation in patients with acute COVID‐19 , 2021, Clinical & translational immunology.

[14]  Nguyen H. Tran,et al.  Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK , 2020, Lancet.

[15]  G. Koh.  Faculty Opinions recommendation of Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK , 2020, Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature.

[16]  Robert T. Chen,et al.  Vaccines based on replication incompetent Ad26 viral vectors: Standardized template with key considerations for a risk/benefit assessment , 2020, Vaccine.

[17]  H. Schuitemaker,et al.  Ad26 vector-based COVID-19 vaccine encoding a prefusion-stabilized SARS-CoV-2 Spike immunogen induces potent humoral and cellular immune responses , 2020, NPJ vaccines.

[18]  H. Schuitemaker,et al.  Ad26 vector-based COVID-19 vaccine encoding a prefusion-stabilized SARS-CoV-2 Spike immunogen induces potent humoral and cellular immune responses , 2020, npj Vaccines.

[19]  Y. Hu,et al.  Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial , 2020, The Lancet.

[20]  Stephen J. Thomas,et al.  A review of Dengvaxia®: development to deployment , 2019, Human vaccines & immunotherapeutics.

[21]  T. Monath,et al.  rVSVΔG-ZEBOV-GP (also designated V920) recombinant vesicular stomatitis virus pseudotyped with Ebola Zaire Glycoprotein: Standardized template with key considerations for a risk/benefit assessment , 2019, Vaccine: X.

[22]  S. Sambhara,et al.  Longevity of adenovirus vector immunity in mice and its implications for vaccine efficacy. , 2018, Vaccine.

[23]  H. Schuitemaker,et al.  Adenoviral vector type 26 encoding Zika virus (ZIKV) M-Env antigen induces humoral and cellular immune responses and protects mice and nonhuman primates against ZIKV challenge , 2018, PloS one.

[24]  S. Gilbert.  Adenovirus-vectored Ebola vaccines , 2015, Expert review of vaccines.

[25]  Stephen Coman,et al.  From development to deployment , 2014 .

[26]  H. Fausther-Bovendo,et al.  Pre-existing immunity against Ad vectors , 2014, Human vaccines & immunotherapeutics.

[27]  Jennifer A. Johnson,et al.  First-in-human evaluation of the safety and immunogenicity of a recombinant adenovirus serotype 26 HIV-1 Env vaccine (IPCAVD 001). , 2013, The Journal of infectious diseases.

[28]  U. Reimer,et al.  Characterization of humoral and cellular immune responses elicited by a recombinant adenovirus serotype 26 HIV-1 Env vaccine in healthy adults (IPCAVD 001). , 2013, The Journal of infectious diseases.

[29]  Laura C. Rosella,et al.  Association between the 2008–09 Seasonal Influenza Vaccine and Pandemic H1N1 Illness during Spring–Summer 2009: Four Observational Studies from Canada , 2010, PLoS medicine.

[30]  J. Mascola,et al.  Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 candidate vaccine delivered by a replication-defective recombinant adenovirus vector. , 2006, The Journal of infectious diseases.

[31]  J. Mascola,et al.  Replication-Defective Adenovirus Serotype 5 Vectors Elicit Durable Cellular and Humoral Immune Responses in Nonhuman Primates , 2005, Journal of Virology.

[32]  S. Kostense,et al.  Immunogenicity of Recombinant Adenovirus Serotype 35 Vaccine in the Presence of Pre-Existing Anti-Ad5 Immunity1 , 2004, The Journal of Immunology.

[33]  J. Shiver,et al.  Recent advances in the development of HIV-1 vaccines using replication-incompetent adenovirus vectors. , 2004, Annual review of medicine.

[34]  R. K. Evans,et al.  Comparative Immunogenicity in Rhesus Monkeys of DNA Plasmid, Recombinant Vaccinia Virus, and Replication-Defective Adenovirus Vectors Expressing a Human Immunodeficiency Virus Type 1 gag Gene , 2003, Journal of Virology.

[35]  R. Chanock,et al.  Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. , 1969, American journal of epidemiology.